Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Anti-Obesity Pharmacotherapy (Class Effect)

Phase 3Small molecule

TThe Cleveland Clinic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CirrhosesRecruiting

Liver CirrhosesPhase 3

Recruiting

Timeline

Expected Milestones

Q1 2034

ApprovedRecruiting

Liver Cirrhoses

NCT07058155

Clinical

Trials by Indication[1]

Liver Cirrhoses1 trial

OPTIMAL Trial: Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Recruiting·TThe Cleveland Clinic·Approved·NCT07058155·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-Obesity Pharmacotherapy (Class Effect). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-Obesity Pharmacotherapy (Class Effect) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-Obesity Pharmacotherapy (Class Effect). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Cleveland Clinic

Related News